💥 Gate Square Event: #PTB Creative Contest# 💥
Post original content related to PTB, CandyDrop #77, or Launchpool on Gate Square for a chance to share 5,000 PTB rewards!
CandyDrop x PTB 👉 https://www.gate.com/zh/announcements/article/46922
PTB Launchpool is live 👉 https://www.gate.com/zh/announcements/article/46934
📅 Event Period: Sep 10, 2025 04:00 UTC – Sep 14, 2025 16:00 UTC
📌 How to Participate:
Post original content related to PTB, CandyDrop, or Launchpool
Minimum 80 words
Add hashtag: #PTB Creative Contest#
Include CandyDrop or Launchpool participation screenshot
🏆 Rewards:
🥇 1st
Conoah and Nuocheng Jianhua jointly announced a licensing agreement with Prolium for CD20xCD3 bispecific antibodies
On January 20th, JIN10 News reported that Connoa and NovaQuest jointly announced that the two companies and their joint venture have reached a licensing agreement with Prolium Bioscience, authorizing Prolium to develop and commercialize the CD20×CD3 bispecific antibody ICP-B02 (CM355). According to the protocol, Prolium will have the rights to develop, register, produce, and commercialize ICP-B02 in the global non-oncology field and the oncology field outside of Asia. NovaQuest and Connoa will receive a total payment of up to $520 million, including upfront and near-term payments, as well as additional payments for achieving clinical development, registration, and commercialization milestones, and both parties will receive a minority equity stake in Prolium. In addition, NovaQuest and Connoa will also receive tiered royalty payments based on future net sales of the product.